ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GRAL vs CAI // EV/EBITDA & P/E VALUATION

GRAIL Inc. (NASDAQ) VS. Caris Life Sciences Inc. (NASDAQ) • 15-METRIC TALLY: GRAL 1 — CAI 10
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GRAL VS. CAI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GRAL CAI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -18.00% 4.40% -22.40 CAI /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 95.0x — TIE /valuation <GO>
Free Cash Flow Yield -4.23% 0.65% -4.88 CAI /fcf-yield <GO>
Operating Margin -60.00% 5.60% -65.60 CAI /operating-margins <GO>
Net Profit Margin -60.00% -8.40% -51.60 CAI /net-margins <GO>
Revenue Growth (YoY) 17.20% 97.00% -79.80 CAI /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 7.26 9.79 -2.53 CAI /balance-sheet <GO>
Piotroski F-Score Quality 6/9 8/9 -2.00 CAI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.0 58.8 -4.80 CAI /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.00 0.91 +0.09 GRAL /macro-sensitivity <GO>
Forward P/E Multiple 22.0x 21.0x +1.00 CAI /forward-pe <GO>
Enterprise Scale & Market Cap $6.41B $9.70B -$3.30B CAI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GRAL REV CAI REV GRAL GROSS % CAI GROSS % GRAL FCF CAI FCF
FY 2025 $147.2M $812.0M — — -$299.9M $66.9M
FY 2024 $125.6M $412.3M — — -$582.4M -$253.6M
FY 2023 $93.1M $306.1M — — -$600.0M -$289.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GRAL // BETA 1.00
CAI // BETA 0.91